For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Catalyst Biosciences, Inc.

USPTO Granted Patents = 26

% Expired Patents = 26.9

CIPO Patents = 8

EPO Patents = 17

Forward Citations = 242

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Edwin L Madison (16 out of 36 patents)

Christopher D Thanos (10 out of 60 patents)

Sandra Waugh Ruggles (4 out of 11 patents)

4. Jack Nguyen (4 out of 4 patents)

5. Vanessa Soros (3 out of 9 patents)

6. Mikhail Popkov (3 out of 11 patents)

7. Grant Ellsworth Blouse (3 out of 3 patents)

8. Howard Levy (2 out of 2 patents)

9. Srinivasa Rao Akireddy (2 out of 14 patents)

10. Balwinder Singh Bhatti (2 out of 43 patents)

11. Daniel Yohannes (2 out of 10 patents)

12. Matt S Melvin (2 out of 6 patents)

13. Yunde Xiao (2 out of 8 patents)

14. Charles S Craik (2 out of 22 patents)

15. Ronald Joseph Heemstra (2 out of 5 patents)

26 patents: Sort by Forward Citations

1. 11491212 - Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B (2022-11-08),

2. 11401513 - Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use (2022-08-02),

3. 11266724 - Modified factor VII polypeptides for subcutaneous administration and on-demand treatment (2022-03-08),

4. 11203749 - Factor VII polypeptides that are modified and uses thereof (2021-12-21),

5. 10982203 - Modified factor IX polypeptides and uses thereof (2021-04-20),

6. 10954501 - Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use (2021-03-23),

7. 10781435 - Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use (2020-09-22),

8. 10716770 - Nicotinic receptor non-competitive antagonists (2020-07-21),

9. 10258582 - Nicotinic receptor non-competitive antagonists (2019-04-16),

10. 10160961 - Factor VII polypeptides that are modified and uses thereof (2018-12-25),

11. 9856467 - Modified factor X polypeptides and uses thereof (2018-01-02),

12. 9795655 - Modified MT-SP1 proteases that inhibit complement activation (2017-10-24),

13. 9476037 - Factor VII polypeptides that are modified and uses thereof (2016-10-25),

14. 9359598 - Mutant MT-SP1 proteases with altered substrate specificity or activity (2016-06-07),

15. 9328339 - Modified factor IX polypeptides and uses thereof (2016-05-03),

Catalyst BioSciences is a clinical-stage biopharmaceutical company focused on developing novel proteases for use in the field of hemostasis, complement disorders, and other serious diseases. With a strong foundation in engineering and customizing proteases, Catalyst is committed to bringing innovative therapies to improve the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Catalyst Biosciences, Inc.

26 Patents

#50 in South San Francisco, CA

#3,037 in California

#12,838 in US

#24,735 in the World

South San Francisco, CA, United States of America

Catalyst Biosciences, Inc.

Forward Citations = 242

26 inventors:

Edwin L Madison (16 out of 36 patents)

Christopher D Thanos (10 out of 60 patents)

Sandra Waugh Ruggles (4 out of 11 patents)

4. Jack Nguyen (4 out of 4 patents)

5. Vanessa Soros (3 out of 9 patents)

Please report any incorrect information to [email protected]

Loading…